Eryptosis in Liver Diseases: Contribution to Anemia and Hypercoagulation
Medical Sciences · 12.08.2025 · 13 (3) · 125
DOI: 10.3390/medsci13030125 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medical Sciences, online erschienen am 12.08.2025. Verfasst von Saulesh Kurmangaliyeva und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Virology, and Immunology, NJSC "West Kazakhstan Marat Ospanov Medical University", 68 Maresyev st, Aktobe 030000, Kazakhs…. Hauptthemen laut MEDLINE: Liver Diseases, Anemia, Eryptosis, Thrombophilia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 160 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Eryptosis is a type of regulated cell death of mature erythrocytes characterized by excessive Ca2+ accumulation followed by phosphatidylserine externalization. Eryptosis facilitates erythrophagocytosis resulting in eradication of damaged erythrocytes, which maintains the population of healthy erythrocytes in blood. Over recent years, a wide array of diseases has been reported to be linked to accelerated eryptosis, which leads to anemia. A growing number of studies furnish evidence that eryptosis is implicated in the pathogenesis of liver diseases. Herein, we summarize the current knowledge of eryptosis signaling, its physiological role, and the impact of eryptosis on anemia and hypercoagulation. In this article, upon systemically analyzing the PubMed-indexed publications, we also provide a comprehensive overview of the role of eryptosis in the spectrum of hepatic diseases, its contribution to the development of complications in liver pathology, metabolites (bilirubin, bile acids, etc.) that might trigger eryptosis in liver diseases, and eryptosis-inducing liver disease medications. Eryptosis in liver diseases contributes to anemia, hypercoagulation, and endothelial damage (via ferroptosis of endothelial cells). Treatment-associated anemia in liver diseases might be at least partly attributed to drug-induced eryptosis. Ultimately, we analyze the concept of inhibiting eryptosis pharmaceutically to prevent eryptosis-associated anemia and thrombosis in liver diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Microbiology, Virology, and Immunology, NJSC "West Kazakhstan Marat Ospanov Medical University", 68 Maresyev st, Aktobe 030000, Kazakhstan.
- BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, 25250 Vestec, Czech Republic.
- Department of Microbiology, Virology, and Immunology, NJSC "South Kazakhstan Medical Academy", Al-Farabi sq, Shymkent 160019, Kazakhstan.
- Institute of Health, National University of Water and Environmental Engineering, 11 Soborna st, 33028 Rivne, Ukraine.
- Rivne Regional Clinical Hospital, 78g Kyivska st, 33007 Rivne, Ukraine.
- Department of Microbiology, NJSC "Semey Medical University", 103 Abay st, Semey 071400, Kazakhstan.
ORCID-Profile: Anton Tkachenko, Liliya Tryfonyuk, Kairat Kurmangaliyev
Zitieren
APA
Kurmangaliyeva, S., Baktikulova, K., Tkachenko, A., Seitkhanova, B., Tryfonyuk, L., Rakhimzhanova, F., Yussupov, R., & Kurmangaliyev, K. (2025). Eryptosis in Liver Diseases: Contribution to Anemia and Hypercoagulation. Medical Sciences, 13(3), 125. https://doi.org/10.3390/medsci13030125
Vancouver
Kurmangaliyeva S, Baktikulova K, Tkachenko A, Seitkhanova B, Tryfonyuk L, Rakhimzhanova F, et al. Eryptosis in Liver Diseases: Contribution to Anemia and Hypercoagulation. Medical Sciences. 2025;13(3):125. doi:10.3390/medsci13030125
BibTeX
@article{Kurmangaliyeva2025,
author = {Kurmangaliyeva, Saulesh and Baktikulova, Kristina and Tkachenko, Anton and Seitkhanova, Bibigul and Tryfonyuk, Liliya and Rakhimzhanova, Farida and Yussupov, Rustam and Kurmangaliyev, Kairat},
title = {Eryptosis in Liver Diseases: Contribution to Anemia and Hypercoagulation},
journal = {Medical Sciences},
year = {2025},
volume = {13},
number = {3},
pages = {125},
doi = {10.3390/medsci13030125}
}
EUVIMED